Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines

Muscle and Nerve

Volumn 22, Issue 11, 1999, Pages 1479-1497

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Adverse reactions; Autoimmune demyelinating neuropathies; Immunomodulation; Inflammatory myopathies; Intravenous immunoglobulin; Myasthenia gravis

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; DERMATOMYOSITIS; DRUG EFFICACY; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MYASTHENIA GRAVIS; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW;

DEMYELINATING AUTOIMMUNE DISEASES, CNS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEUROMUSCULAR DISEASES; POLYRADICULONEUROPATHY; PRACTICE GUIDELINES;

EID: 0032707209     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B     Document Type: Review

References (154)

1. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
2. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1993;43:876-879.
3. Ankrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIg) in vivo downregulatory effects on the IL-1 system. Clin Exp Immunol 1999;115:136-143.
4. Arakawa Y, Yoshimura M, Kobayashi S, Ichihashi K. The use of intravenous immunoglobulin in Miller-Fisher syndrome. Brain Dev 1993;15:231-233.
5. Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-443.
6. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
7. Asham N. Intravenous immunoglobulin induced nephropathy: a complication of IVIg therapy. J Nephrol 1998;11: 157-161.
8. Ahsan N, Palmer BF, Wheeler D, Greenlee RG, Jr., Toto RD. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-1987.
9. Azulay JP, Blin O, Pouget J, Bille-Turc F, Carles G, Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with and-GM1 antibodies. Neurology 1994;44:429-432.
10. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effect of intravenous immunoglobulin (IVIg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-683.
11. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
12. Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 1996;71:227-229.
13. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin. J Clin Invest 1989;1974-1981.
14. Benito-León J, López-Ríos F, Rodríguez-Martín, Madero S, Ruiz J. Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy. J Neurol Sci 1998;158:113-117.
15. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.
16. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996; 19:388-391.
17. Björkander J, Hammarströlm L, Smith E, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987;7:8-15.
18. Blasczyk R, Westhoff V, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
19. Blick KE, Liles SM. Principles of clinical chemistry. New York: Wiley; 1985. p 401-404.
20. Boom BW, Brand A, Bavinek JB, Earnisse JG, Daha MR, Vermeer BJ. Severe leucocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose immunoglobulin intravenously. Arch Dermatol 1988;124:1550-1553.
21. Bouche P, Moulonguet A, Ben Younes-Chennoufi A, Adams D, Baumann N, Meininger V, Leger JM, Said G. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38-44.
22. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677.
23. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, Province MA, and the CIDD Group. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on natural history. Muscle Nerve 1983;6:91-103.
24. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986;314:560-564.
25. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036.
26. Chan-Lam D, Fitzsimmons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1982;i:1436.
27. Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB, Freimer ML, Miller RG, Griffin JW. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-242.
28. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P. Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am J Med 1991;91:162-168.
29. Choudhary PP, Hughes RAC, Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995;88:493-502.
30. Constantinescu CS, Chang AP, McClusky LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-584.
31. Cook D, Dalakas MC, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.
32. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991;84:81-84.
33. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-1893.
34. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-1498.
35. Dalakas MC. Aseptic meningitis and intravenous immunoglobulin. Ann Intern Med 1995;122:316-317.
36. Dalakas MC. Autoimmune peripheral neuropathies. In: Rich RR, editor. Clinical immunology. St. Louis, MO: Mosby Yearbook; 1995. p 1377-1394.
37. Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995;37 (suppl):2-13.
38. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37(suppl):74-86.
39. Dalakas MC. Clinical relevance of IVIg in the modulation of the complement-mediated tissue damage: implications in dermatomyositis, Guillain-Barré syndrome and myasthenia gravis. In: Kazatchkine M, Morel D, editors. Intravenous immunoglobulin research and therapy. London: Parthenon; 1996. p 89-93.
40. Dalakas MC. Experience with IVIg in the treatment of inflammatory myopathies. In: Kazatchkine M, Morel D, editors. Intravenous immunoglobulin research and therapy. London: Parthenon; 1996. p 275-284.
41. Dalakas MC. The treatment of polymyositis, dermatomyositis and inclusion body myositis. In: Johnson RT, Griffin JW, editors. Current therapy in neurology. St. Louis, MO: Mosby Yearbook; 1996. p 407-412.
42. Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology 1997;48(suppl): 64-69.
43. Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997;126:721-730.
44. Dalakas MC. Meningitis and skin reactions after intravenous immunoglobulin therapy. Ann Intern Med 1997;127:1130.
45. Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 1998;51 (suppl):S37-S45.
46. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51 (suppl):S2-S8.
47. Dalakas MC. The use of intravenous immunoglobulin for neurologic diseases. Neurology 1998;51(suppl 5).
48. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000.
49. Dalakas MC, Pezeshkpour GH, Gravell M, Sever JL. Polymyositis in patients with AIDS. JAMA 1986;256:2381-2383.
50. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, Cupler EJ, Sekul EA, Otero C. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.
51. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study. Neurology 1997;48: 712-716.
52. Dalakas MC, Sonies B, Koffman B, Spector S, Sivakumar K, Cupler E, Lopez-Devine J. High-dose intravenous immunoglobulin (IVIg) combined with prednisone in the treatment of patients with inclusion-body myositis (IBM): a double blind, randomised controlled trial. Neurology 1997;48:332.
53. Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S. Effect of high-dose intravenous immunoglobulin (IVIg) on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994;51:861-864.
54. Diegel M. Rankin B Bolen J. Dubois P, Kiener P. Cross linking of Fc receptor to surface immunoglobulin on B cells provides on inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994;269:11409-11416.
55. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human antithyroglobulin autoantibodies. J Clin Invest 1990;85:620-629.
56. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
57. Dutch Guillain-Barré Syndrome Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35:749-752.
58. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
59. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994:36:838-845.
60. Eibl MM, Wedgood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989;1(suppl):1-42.
61. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327: 1032-1033.
62. Elliott JL, Pestronk A. Progression of multifocal motor demyelinating neuropathy during apparently successful treatment with human immunoglobulin. Neurology 1994;44: 967-968.
63. French Cooperative Group on Plasma Exchange in Guillain - Barré Syndrome. Efficiency of plasma exchange in Guillain - Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-761.
64. Fujii M, Koffman B, Sivakumar K, Dalakas MC. Histologic characteristics in repeated muscle biopsies of patients with inclusion body myositis (IBM) treated in a control trial with high-dose intravenous immunoglobulin (IVIg) and prednisone. Neurology 1997;48:332-333.
65. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RAC. Human immunoglobulin ameliorates rat experimental allergic neuritis. Brain 1997:120;1533-1540.
66. Gajdos PH, Chevret S, Clair B, Trenchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41: 789-796.
67. Gajdos Ph, Outin H, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphael JC, Goulon M, Goulon-Goeau C, Morel E. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;i:406-407.
68. Gajdos P, Outin HD, Morel E, Raphael JC, Goulon M. High dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange? Ann NY Acad Sci 1987;505: 843-844.
69. Gordon DS. Innovative use of intravenous immunoglobulin in clinical hematology. Am J Med 1987;83(suppl 4A):1-56.
70. Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
71. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma exchange/sandoglobulin Guillain-Barré syndrome trial group. Ann Neurol 1998;44:780-788.
72. Hague RA, Eden DB, Yap PL, Mok JYO, Rae P. Hyperviscosity in HIV infected children: a potential hazard during intravenous immunoglobulin therapy. Blut 1990;61:66-67.
73. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998;51:16-21.
74. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
75. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome - part II. Muscle Nerve 1995;18:154-164.
76. Heafield MT, Gammage MD, Nightingale S, Williams AC. Idiopathic dysautonomia treated with intravenous gammaglobulin, Lancet 1996;347:28-29.
77. Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, McKhann GM. Patterns of clinical recovery in Guillain-Barré syndrome. Neurology 1997;48:695-700.
78. Howard JF. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 51(suppl): 1998;51:S30-S36.
79. Ippoliti G, Cosi V, Piccolo G, Lombardi M, Mantegazza R. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;2:809.
80. Irani DN, Cornblath DR, Chaundhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-875.
81. Jan S, Beretta S, Moggio M, Alobbati L, Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992; 55:60-64.
82. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous gammaglobulin. Lancet 1991;337:1137-1139.
83. Jungi TW, Nydegger VE. Proposed mechanisms of action of intravenous IgG in autoimmune diseases. Transfus Sci 1992; 13:267-290.
84. Kanra G, Uzon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Pediatr Neurol 1997;1: 7-12.
85. Kaveri S, Prasad N, Vassilev T, Hurez V, Pashov A, Lacroix-Desmazes S, Kazatchkine M. Modulation of autoimmune responses by intravenous immunoglobulin. Mult Scler 1997;3: 121-128.
86. Kaveri S, Vassilev T, Hurex V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz, Kazatchkine MD. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-869.
87. Kazatchkine MD, Dietrich G, Hurez, V, Ronda N, Bellon B, Rossi F, Kaveri SV. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994;139:79-107.
88. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998; 351:184-185.
89. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997;20:1102-1107.
90. Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIg preparations: in vivo study in naive mice. J Clin Immunol 1998;18:52-60.
91. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52:1053-1061.
92. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773-781.
93. Kurlander RJ, Hall J. Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010-2018.
94. Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology 1998;51: 1656-1660.
95. Lang B, Laxer RM, Murphy G, Silverman ED, Roitmani CM. Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 1991;91:169-172.
96. Lecky BRF. Gammaglobulin treatment in neurology. Fundamentals and clinical applications. J Neurol Neurosurg Psychiatry 1994;57(suppl 1).
97. Leger JM, Ben Younes-Chennoufi A, Chassande B, Davila G, Bouche P, Baumann N, Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994;57(suppl):46-49.
98. Leon-Monzon M, Dalakas MC. Interleukin-1 (IL-1) is toxic to human muscle. Neurology 1994;44(suppl):132.
99. Leung DYM, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987;79:468-472.
100. Liblau R, Gajdos PH, Bustardet FA, El Habib R, Bach JF, Morel E. Intravenous gamma globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991;11:128-131.
101. Malik U. Oleksowicz L, Latov N, Cardo LJ. Intravenous γ-globulin inhibits binding of anti-GMI to its target antigen. Ann Neurol 1996:39:136-139.
102. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T cell receptor Vβ chain. Proc Natl Acad Sci USA 1992:89:3325-3329.
103. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998;65:107-110.
104. Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997;62:529-531.
105. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1997;63:765-769.
106. Moll JW, Henzen-Logmans SC, Van der Meche FG, Vecht CH. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 1993;56:112-115.
107. Morbidity and Mortality Weekly Report. Outbreak of hepatitis C associated with intravenous immunoglobulin administration, United States, October 1993-June 1994. MMWR 1994;43:505-509.
108. Nagappon R, Barker J. Second response to immunoglobulin in recurrent Guillain-Barré syndrome. NZ Med J 1998;13: 433-434.
109. Nevo V, Pestronk A, Kornberg AJ, et al.: Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996;47:98-102.
110. Newburger JW, Takahashi M, Berser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639.
111. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993;43:537-544.
112. Pascual J, Cid C, Berciano J. High-dose intravenous immunoglobulin for peripheral neuropathy associated with Sjogren's syndrome. Neurology 1998;51:650-651.
113. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet 1997;349:225-230.
114. Qurshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-632.
115. Rees JH, Gregson NA, Hughes RAC. Antiganglioside antibodies in Guillain Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-816.
116. Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996;14:308-312.
117. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994;71:309-314.
118. Romano JG, Rotta FT, Potter P, Rosenfeld V, Santibanez R, Rocha B, Bradley WG. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 1998;21:1327-1330.
119. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990;144:1387-1392.
120. Said G, Goulon-Gorean C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559-569.
121. Sater RA, Rostami A. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin. Neurology 1998;51:9-15.
122. Schiff RJ. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-1650.
123. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121: 259-262.
124. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.
125. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 1997;20:1569-1575.
126. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
127. Stangel M, Hartung H-P, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998;153:203-214.
128. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1181.
129. Sticker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous γ-globulin. Arch Neurol 1993;50:837-840.
130. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533-2539.
131. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91: 602-607.
132. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988;25:41-48.
133. Triggs WJ, Young MS, Eskin T, Valenstein E. Treatment lumbosacral plexopathy with intravenous immunoglobulin. Muscle Nerve 1997;20:244-246.
134. Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry 1996;60:388-392.
135. Uher F, Dickler HB. Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function. J Immunol 1986; 137: 3124-3129.
136. Van den Berg LH, Franssen H, Wokke JHJ. The long term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121:421-428.
137. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FG, Wokke JH. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
138. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
139. Van der Meche FG, van Doorn PA. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 1997;20:136-147.
140. van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatmerit in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study (see comments). Neurology 1990;40:209-212.
141. van Doorn PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1991;48:217-220.
142. van Engelson BGM, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;57(suppl):65-68.
143. Varela F, Andersson A, Dietrich G, Sundblad A, Holmberg D, Kazatchkine M, Coutinho A. The population dynamics of antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991;88:5917-5921.
144. Vassilev T, Gelin C, Kaveri SV, Xilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92: 369-372.
145. Vermeulen M, van Doorn PA, Brand A, Strengers PFW. Jennekens FGI, Busch HGM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
146. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon N, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282: 490-493.
147. Visser LH, van der Meche FG, Meulstee J, van Doorn PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry 1998;64:242-244.
148. Voltz RV, Rosen F, Yousry T, Beck J. Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a GBS patient treated with IV immunoglobulin. Neurology 1996;46: 250-251.
149. Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol 1999;95:174-184.
150. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 1994;17:1494-1495.
151. Woodruff RK, Griff AP, Firkin FL, Smith IL. Fatal thrombic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;ii:217-218.
152. Younger DS, Rosoklija G, Hays AP, Trojaborg W, Latov N. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996;19:722-777.
153. Yu Z, Lennon VA, Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-228.
154. Yuki N, Miyaga F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 1996;139:160-162.